Novacyt (LON:NCYT) Issues Earnings Results

Novacyt (LON:NCYT) posted its earnings results on Thursday. The company reported GBX (33) earnings per share (EPS) for the quarter, Digital Look Earnings reports. The business had revenue of GBX 2,003 million during the quarter. Novacyt had a negative net margin of 125.04% and a negative return on equity of 62.56%.

Novacyt Stock Down 4.2%

LON NCYT traded down GBX 1.32 during trading on Thursday, reaching GBX 30.33. The company’s stock had a trading volume of 147,641 shares, compared to its average volume of 46,286. The company has a current ratio of 5.03, a quick ratio of 4.46 and a debt-to-equity ratio of 26.81. The stock has a market capitalization of £21.98 million, a PE ratio of -0.71 and a beta of 1.06. The business has a 50-day moving average price of GBX 32.93 and a 200-day moving average price of GBX 35.72. Novacyt has a 1-year low of GBX 29.50 and a 1-year high of GBX 54.

About Novacyt

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
· Precision Medicine: DPYD genotyping assay
· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
· Ranger® Technology: automated DNA sample preparation and target enrichment technology
MyGo: real-time quantitative PCR (qPCR) instruments

Research Use Only
Range of services for the life sciences industry:
· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries.